MA55093A - Méthodes et compositions pour le traitement du cancer - Google Patents

Méthodes et compositions pour le traitement du cancer

Info

Publication number
MA55093A
MA55093A MA055093A MA55093A MA55093A MA 55093 A MA55093 A MA 55093A MA 055093 A MA055093 A MA 055093A MA 55093 A MA55093 A MA 55093A MA 55093 A MA55093 A MA 55093A
Authority
MA
Morocco
Prior art keywords
cancer
compositions
treatment
methods
Prior art date
Application number
MA055093A
Other languages
English (en)
Inventor
Graeme Currie
Original Assignee
Fusion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Pharmaceuticals Inc filed Critical Fusion Pharmaceuticals Inc
Publication of MA55093A publication Critical patent/MA55093A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA055093A 2019-03-01 2020-03-03 Méthodes et compositions pour le traitement du cancer MA55093A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962812929P 2019-03-01 2019-03-01
US201962856216P 2019-06-03 2019-06-03
US201962907504P 2019-09-27 2019-09-27

Publications (1)

Publication Number Publication Date
MA55093A true MA55093A (fr) 2022-01-05

Family

ID=72235995

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055093A MA55093A (fr) 2019-03-01 2020-03-03 Méthodes et compositions pour le traitement du cancer

Country Status (9)

Country Link
US (1) US20200277387A1 (fr)
EP (1) EP3930705A4 (fr)
AU (1) AU2020232695A1 (fr)
IL (1) IL285796A (fr)
MA (1) MA55093A (fr)
MX (1) MX2021010449A (fr)
SG (1) SG11202109336UA (fr)
WO (1) WO2020180898A1 (fr)
ZA (1) ZA202107139B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2549769T3 (es) 2009-03-25 2015-11-02 Genentech, Inc. Anticuerpos anti-FGFR3 y métodos que emplean los mismos
AU2016374441B2 (en) 2015-12-17 2021-10-21 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
WO2022092085A1 (fr) * 2020-10-28 2022-05-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Composition pharmaceutique pour le traitement de tumeurs
WO2024104922A1 (fr) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Procédé d'amélioration de la fonction musculaire squelettique
KR20250162619A (ko) 2023-03-20 2025-11-18 아센디스 파마 그로우쓰 디스오더스 에이/에스 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법
WO2026020109A1 (fr) * 2024-07-19 2026-01-22 Tyra Biosciences, Inc. Traitement combiné comprenant un inhibiteur de fgfr3 et un inhibiteur de pd-1/pd-l1 destiné à être utilisé dans le traitement du cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2549769T3 (es) * 2009-03-25 2015-11-02 Genentech, Inc. Anticuerpos anti-FGFR3 y métodos que emplean los mismos
SG11201706727XA (en) * 2015-02-19 2017-09-28 Bioclin Therapeutics Inc Methods, compositions, and kits for treatment of cancer
CN110785184A (zh) * 2017-02-06 2020-02-11 雷尼尔医疗公司 用于治疗癌症的方法，组合物和试剂盒

Also Published As

Publication number Publication date
MX2021010449A (es) 2021-09-21
WO2020180898A8 (fr) 2020-10-29
EP3930705A4 (fr) 2023-09-06
AU2020232695A1 (en) 2021-10-28
EP3930705A1 (fr) 2022-01-05
SG11202109336UA (en) 2021-09-29
US20200277387A1 (en) 2020-09-03
IL285796A (en) 2021-10-31
ZA202107139B (en) 2024-03-27
WO2020180898A1 (fr) 2020-09-10

Similar Documents

Publication Publication Date Title
EP3947715A4 (fr) Procédés et compositions pour le traitement du cancer
EP3894392A4 (fr) Compositions et procédés pour le traitement du cancer
EP3368559A4 (fr) Compositions et méthodes pour le du traitement du cancer
EP3983445A4 (fr) Compositions et méthodes de traitement du cancer
EP3681498A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3908601A4 (fr) Procédés et compositions pour le traitement du cancer
EP4149547A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3462883A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3638293A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3688023A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3347025A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3968987A4 (fr) Méthodes et substances pour le traitement du cancer
EP3873205A4 (fr) Substances et méthodes pour le traitement du cancer
EP3870104A4 (fr) Méthodes et substances pour le traitement du cancer
EP3353204A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3723733A4 (fr) Méthodes et compositions pour le traitement du cancer utilisant des exosomes associés à l'édition génique
EP3478284A4 (fr) Composés et compositions pour le traitement du cancer
EP3793544A4 (fr) Compositions bifonctionnelles pour le traitement du cancer
EP3773625A4 (fr) Méthodes et matériels pour le traitement du cancer
EP3893902A4 (fr) Compositions et méthodes utiles pour le traitement du cancer colorectal d'aspect crénelé
EP3638270A4 (fr) Compositions et méthodes pour l'amélioration d'un traitement par hyperthermie
EP3877514A4 (fr) Compositions et procédés pour le traitement du cancer
EP3452044A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3987032A4 (fr) Méthodes et compositions permettant le traitement du cancer
EP3638287A4 (fr) Méthodes et compositions pour le traitement d'une inflammation microbienne